{"name":"Ocumension (Hong Kong) Limited","slug":"ocumension-hong-kong-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OT-101 Ophthalmic Solution","genericName":"OT-101 Ophthalmic Solution","slug":"ot-101-ophthalmic-solution","indication":"Corneal neovascularization and scarring","status":"phase_3"}]}],"pipeline":[{"name":"OT-101 Ophthalmic Solution","genericName":"OT-101 Ophthalmic Solution","slug":"ot-101-ophthalmic-solution","phase":"phase_3","mechanism":"OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye.","indications":["Corneal neovascularization and scarring","Alkali burn of the eye"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPOURLUFZqLWVPQmg0ZkxkdnhlcW9Vcmw4bkhqa0UwckV6WmdhQVRrSkU2ZllQREJiamYwMGZ4LWpVNmR0MGlyUVFKb1RxMmlNZTRnVjNza0h6QTdNR3p4OUoyV2tZSy1vZHhqQXJHVTQ0RGxvbVVndzZQSm9jTVhTaUxJb3dodDhOaDJlVUppZVo4TjRRZG93djR0THpNY2xFOE05T0pGUEp2NUh3Rm9yTFA3cmlObUMxamUtSjZQTlRnYlI5aHZncTFtaFZxeWRjTHV4NmpIQmxFdGQ4a0MxczNBTUNUOWtJbG5xaDZkQkxJQWlOSGlLZW9zMFc4TlloNnpLc2NOZElOeTFkQ21Zb2t1Vmh1eVY4T3VmQnExYVBQc0lGa1ZEUkFHdGI5SkkwRHFz?oc=5","date":"2026-03-17","type":"trial","source":"Mena FN","summary":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., LTD, 2Eyesvision, Carl Zeiss AG, Alcon, Coopervision, Topcon Healthcare - Mena FN","headline":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., L","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-19","type":"trial","source":"PR Newswire","summary":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Ther","headline":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNek5BaXAzckhLbU4zQzNteHFETGhtbGNFUjhLQnRiX2RZZlFsSWhrbTF4VU1HUHlZVE1yOHNLU0RRbURZOWoyUkVkcmt5bHpUamZaY09lNVVHMzZUN3cxNXhsU0ZhWDNtbjRwa1VZWWwxZzFlc1hCV1M5V010c241QnhFLVVncVU1dmVvdnZQMzJYMlRPeWNLSVlKRko2eWRyU1A3LUpnVHdWd01zUms0VzJFTFE1YU1QcXNTS09oakh0UQ?oc=5","date":"2022-06-21","type":"pipeline","source":"BioWorld News","summary":"China’s NMPA gives green light to Ocumension’s Yutiq intravitreal implant for uveitis - BioWorld News","headline":"China’s NMPA gives green light to Ocumension’s Yutiq intravitreal implant for uveitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPRzZWVDVsUlFfbm5uaG9lTXc0cUdHVE9IejJGOGxZbWxmTWRnQk43VkYyRDQycXQxZ3h2S3Itd001dk5ldGFzSGZtbXRiYW5uOXg4Wk12TENXeXhTRG5VSTVBenBBaUF3TWRneHN2RUU3THRzdDNGSWZBczVnMDNPUUFmV3BNRUhkTFlwa2VFQnBxWF9XZkpEUi1QdVhNTTk4ZlE?oc=5","date":"2020-05-25","type":"pipeline","source":"The Standard (HK)","summary":"Eye-care therapy maker has four drug candidates - The Standard (HK)","headline":"Eye-care therapy maker has four drug candidates - The Standard (HK)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}